J Obes Metab Syndr.
2018 Mar;27(1):1-3. 10.7570/jomes.2018.27.1.1.
Sodium-Glucose Co-transporter 2 Inhibitor: The Magic Bullet for Obesity in Diabetes?
- Affiliations
-
- 1Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University Ansan Hospital, Korea University College of Medicine, Ansan, Korea. seo-ji-a@hanmail.net
- KMID: 2410870
- DOI: http://doi.org/10.7570/jomes.2018.27.1.1
Abstract
- No abstract available.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Response: Predictors of the Therapeutic Efficacy and Consideration of the Best Combination Therapy of Sodium-Glucose Co-transporter 2 Inhibitors (Diabetes Metab J 2019;43:158–73)
- Letter: Predictors of the Therapeutic Efficacy and Consideration of the Best Combination Therapy of Sodium-Glucose Co-transporter 2 Inhibitors (Diabetes Metab J 2019;43:158–73)
- Paradigm Changes in Diabetes Management Guidelines: American Diabetes Association 2018
- Sodium-Glucose Cotransporter 2 Inhibitors: Mechanisms of Action and Various Effects
- Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor
